regulatory
confidence high
sentiment positive
materiality 0.60
Quoin Pharma gets Japan MHLW Orphan Drug Designation for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals, Ltd.
- Japan MHLW granted Orphan Drug Designation to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments.
- Designation provides incentives including up to 10 years of market exclusivity upon approval, priority review, and tax breaks.
- Adds to prior U.S. FDA Orphan Drug, Pediatric Rare Disease, and Fast Track designations, plus EMA Orphan Drug Designation.
- Quoin plans to self-commercialize QRX003 in Japan, U.S., and Western Europe; pivotal Phase 3 study expected H2 2026, NDA filing in 2027.
- Company working with Japanese clinicians to refine clinical/regulatory pathway for approval.